Edwards Lifesciences Q3 sales up 15% to $1.3B; EPS $0.54; guidance reaffirmed

Edwards Lifesciences Corp

2021-Q3 EPS reported $1.85 revenue$3,902,800,000

Q3 sales $1.3B, up 15% reported (14% underlying); TAVR sales $858M, up 15% (14% underlying).
Adjusted EPS $0.54; full-year 2021 sales guidance unchanged at $5.2-$5.4B; adjusted EPS guided to high end of $2.07-$2.27.
TMTT sales $22M; company on track for U.S. approval of PASCAL platform for degenerative mitral regurgitation late 2022.
Free cash flow $471M in Q3, $1.1B YTD; cash and investments $3.1B, total debt $596M.
Q4 2021 guidance: sales $1.30-$1.38B, TAVR $850-$910M, adjusted EPS $0.53-$0.59.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.